Schemes of implementation in NMR of quantum processors and Deutsch-Jozsa algorithm by using virtual spin representation

Schemes of experimental realization of the main two qubit processors for quantum computers and Deutsch-Jozsa algorithm are derived in virtual spin representation. The results are applicable for every four quantum states allowing the required properties for quantum processor implementation if for qubit encoding virtual spin representation is used. Four dimensional Hilbert space of nuclear spin 3/2 is considered in details for this aimComment: 15 pages, 3 figure

Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry

Objective: The soluble guanylate cyclase stimulator riociguat is approved for the treatment of adult patients with pulmonary arterial hypertension (PAH) and inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) following Phase

Representing school discourse stimuli

Discourse study in contemporary science is characterized by various approaches, whose integrative feature is the fact that this theoretical phenomenon is considered as a communicative activity and is caused by anthropocentric factors of speech generation. The representation of school discourse stimuli allows simulating the speech portrait of participants in educational activities. School discourse is a complex communicative phenomenon created by the subjects of the school educational process. It reflects the totality of accepted values and behavioral stereotypes in a particular socio-cultural space. The work aims to investigate the stimuli of school discourse. This work was conducted employing methods, such as 1) the free associative experiment; 2) quantitative analysis, which allowed identifying the actualization of the incentive perception based on quantitative data; and 3) discursive and conceptual analysis, which involved the identification of concepts, simulating them based on the conceptual totality of the means of their lexical representation in the usage. In the course of conducted study, about 600 native speakers of the Russian language were interviewed, and 9,440 associations were obtained for the school discourse stimuli. In the language consciousness of schoolchildren and teachers, associations for the “Family” stimulus were dominant, and the associative field of this stimulus was represented most broadly. The smallest number of associations was noted with regard to the “Evil” stimulus. The frequency of associations in the stimuli “Good”, “Happiness”, “Love”, “Friendship”, “Joy”, and “Labor” was approximately the same. The representation of school discourse stimuli reflects the value system, worldviews, moods, and assessments of recipients. Such a study was conducted for the first time

Mineral supply for sustainable development requires resource governance

International audienceSuccessful delivery of the United Nations sustainable development goals and implementation of the Paris Agreement requires technologies that utilize a wide range of minerals in vast quantities. Metal recycling and technological change will contribute to sustaining supply, but mining must continue and grow for the foreseeable future to ensure that such minerals remain available to industry. New links are needed between existing institutional frameworks to oversee responsible sourcing of minerals, trajectories for mineral exploration, environmental practices, and consumer awareness of the effects of consumption. Here we present, through analysis of a comprehensive set of data and demand forecasts, an interdisciplinary perspective on how best to ensure ecologically viable continuity of global mineral supply over the coming decades

Evinacumab for Homozygous Familial Hypercholesterolemia

BACKGROUND Homozygous familial hypercholesterolemia is characterized by premature cardiovascular disease caused by markedly elevated levels of low-density lipoprotein (LDL) cholesterol. This disorder is associated with genetic variants that result in virtually absent (null–null) or impaired (non-null) LDL-receptor activity. Loss-offunction variants in the gene encoding angiopoietin-like 3 (ANGPTL3) are associated with hypolipidemia and protection against atherosclerotic cardiovascular disease. Evinacumab, a monoclonal antibody against ANGPTL3, has shown potential benefit in patients with homozygous familial hypercholesterolemia. METHODS In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned in a 2:1 ratio 65 patients with homozygous familial hypercholesterolemia who were receiving stable lipid-lowering therapy to receive an intravenous infusion of evinacumab (at a dose of 15 mg per kilogram of body weight) every 4 weeks or placebo. The primary outcome was the percent change from baseline in the LDL cholesterol level at week 24. RESULTS The mean baseline LDL cholesterol level in the two groups was 255.1 mg per deciliter, despite the receipt of maximum doses of background lipid-lowering therapy. At week 24, patients in the evinacumab group had a relative reduction from baseline in the LDL cholesterol level of 47.1%, as compared with an increase of 1.9% in the placebo group, for a between-group least-squares mean difference of –49.0 percentage points (95% confidence interval [CI], –65.0 to –33.1; P 0.001); the between-group least-squares mean absolute difference in the LDL cholesterol level was –132.1 mg per deciliter (95% CI, –175.3 to –88.9; P 0.001). The LDL cholesterol level was lower in the evinacumab group than in the placebo group in patients with null–null variants (–43.4% vs. +16.2%) and in those with non-null variants (–49.1% vs. –3.8%). Adverse events were similar in the two groups. CONCLUSIONS In patients with homozygous familial hypercholesterolemia receiving maximum doses of lipid-lowering therapy, the reduction from baseline in the LDL cholesterol level in the evinacumab group, as compared with the small increase in the placebo group, resulted in a between-group difference of 49.0 percentage points at 24 weeks. (Funded by Regeneron Pharmaceuticals; ELIPSE HoFH ClinicalTrials.gov number, NCT03399786.